Circulating noggin levels following treatment with denosumab or teriparatide in postmenopausal women with low bone mass

What Was Tested

This observational study looks at Teriparatide.

Noggin inactivates bone morphogenetic proteins (BMPs), possibly exerting negative effects on the skeleton.the researchers aimed to compare the effect of agents with opposite impact on bone turnover on noggin circulating levels.

Who Took Part

The age groups tagged for this paper are middle-aged adults, older adults and people over 80, women only.

In this observational, open label, non-randomized clinical study postmenopausal women with low bone mass were treated with either denosumab (n=30) or teriparatide (n=30).

Serum samples were obtained at baseline, three and twelve months after treatment initiation.

How the Study Was Run

The design is described as open-label.

Everyone knew when Teriparatide was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

Prevalent fractures were recorded at baseline and lumbar spine bone mineral density (LS BMD) was measured at baseline and twelve months.

Measured parameters included noggin, BMP-2, BMP-4, procollagen type 1 N-terminal propeptide (P1NP) and C-terminal cross-linking telopeptide of type 1 collagen (CTx).

What Was Measured

PubMed files the paper under topics including Bone Density Conservation Agents, Carrier Proteins, Denosumab, Osteoporosis, Postmenopausal, Teriparatide and Noggin Protein.

The authors tagged it with the keywords BMP.

What This Means in Plain Language

The paper is an open-label study of Teriparatide.

Results are reported in around 4 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2019 (Journal of musculoskeletal & neuronal interactions), a journal based in Greece.

More context: the Teriparatide compound page, all human trials.